Livalo pitavastatin: Phase III data

Data from a double-blind, active-controlled, European Phase III trial in 830 patients showed that pitavastatin met the primary endpoint of non-inferiority to Lipitor atorvastatin, as measured by reduction of LDL-C from baseline at 12 weeks. The reductions in LDL-C were sustained for 52 weeks in a study extension. Patients received 2 or 4 mg pitavastatin or 10 or 20 mg Lipitor. Pitavastatin and Lipitor had similar adverse events. Data were presented at the European Society of Cardiology Congress meeting in Barcelona. Lipitor is marketed by Pfizer Inc. (NYSE:PFE; New York, N.Y.). ...